Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.
A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass ...
Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
Comprehensive study exposes critical health risks of obesity, including diabetes, heart disease, and cancer, while offering ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
A new study finds that three quarters of American adults and half of adolescents are too heavy. That's making more of us sick ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback